While the study population was treated with NAT throughout sample collection, prior work demonstrates that treatment status does not affect ethnicity-associated differences in circulating plasmablast levels during MS,22 or intrathecal IgG. This evidence concerns the gene BRD2 and myeloid sarcoma.